Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morpheus-Liver: Immunotherapy Combinations for Advanced Liver Cancers
2023-506611-17-00Phase 2Authorised
- Sponsor
- Roche
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC) (10 arms), sponsored by Roche. Primary endpoints: Objective response rate, Adverse events and laboratory abnormalities and 2 more. Planned start May 2024; status: authorised.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-506611-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506611-17-00.